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1. INTRODUCTION 
 
Pain as an unpleasant sensory and emotional experience associated with 
actual or potential tissue damage or described in terms of such damage. 
Pain is an unpleasant subjective sensation which can only be experienced 
and not expressed, especially in children who would seem to conceal their 
feelings when suffering from pain. The primary reason to treat or prevent pain is 
humanitarian and this becomes even more important in children who rely 
completely on their parents or care givers for their well being. 
Acute pain is associated with a brief episode of tissue damage or 
inflammation such as that caused by trauma or surgery.  In most of the cases the 
intensity of  the pain diminishes steadily over a period of time. The various 
methods of pain relief have their own disadvantages which prohibit their use in 
children for eg: narcotics in children because of their respiratory depression and 
other analgesics which cannot be given for sometime after general anaesthesia 
due to the fear of vomiting and aspiration, the objection to the needles in the 
case of parenterally administered analgesics. 
The regional anaesthetic techniques significantly decreases post operative 
pain and systemic analgesic requirements. Caudal route was chosen for this 
study as it is one of the simplest and safest techniques in paediatric surgery with 
a high success rate. Epidural space in children favours rapid longitudinal spread 
of drugs and makes it effective in treating postoperative pain. 
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In this study caudal block was done after the induction of general 
anaesthesia and was used as an adjunct to intraoperative anesthesia as well as 
postoperative analgesia in children undergoing surgical procedures below the 
level of the umbilicus. Caudal analgesia reduces the amount of inhaled and 
intravenous anaesthetic drug requirement attenuates the stress response to 
surgery, facilitates a rapid, smooth recovery and provides good postoperative 
analgesia. In order to decrease intra operative and postoperative analgesic 
requirements and to prolong duration of analgesia after single shot caudal 
epidural blockade, various additives such as morphine, fentanyl, clonidine and 
ketamine with local anaesthetics have been studied.   
Ropivacaine is a new long acting amino amide local anaesthetic agent. It 
is structurally related to bupivacaine and has been used for pediatric caudal 
analgesia. It provides pain relief with less motor blockade. Literature suggests 
that ropivacaine is less cardiotoxic than bupivacaine, hence ropivacaine may be 
a more suitable agent for caudal epidural analgesia especially in day care 
surgery.  
Dexmedetomidine is a α2 adrenergic receptor agonist. It has increased 
affinity to α2 adrenergic receptors than clonidine and less α1 adrenergic receptor 
actions. The main advantage of the dexmedetomidine is it higher selectivity 
were compared in Clonidine for α2A receptor is responsible for analgesic, 
hypnotic and anxiolytic actions.  
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The objective of this study was to compare of  the analgesic action of 
clonidine and dexmedetomidine combined with ropivacaine in caudal analgesia 
for children undergoing infra umblical surgical procedures. 
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2. HISTORY 
1901  –  SICARD and CATHELIN described epidural injection through 
sacral hiatus 
1933  –  CAMBEL M.F first described sacral epidural block in children 
and infants 
1957  –  Synthesis of Ropivacaine.  
 
1960 - Clonidine hydrochloride was introduced.   
 
1965 - Melzock and Walts propounded the Gate Control Theory of 
pain. 
 
1974 - KAY B used caudal block for post operative pain relief in    
children. 
1992 -  Ropivacaine was introduced in clinical practice.  
1999 - Dexmedetomidine was introduced in clinical practice. 
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3.  AIM OF THE STUDY 
1. To assess and compare the efficacy of dexmedetomidine and clonidine 
used as adjuncts to ropivacaine in caudal analgesia for children. 
2. Duration of postoperative analgesia and the complications were also 
studied. 
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4. ANATOMY RELATED TO CAUDAL BLOCK 
Anatomy of sacrum 
Sacrum is a large wedge shaped bone. It is formed by fusion of the five 
sacral vertebrae. It articulates above with 5th lumbar vertebra and below with the 
coccyx .It has an anteriorly concave and posteriorly convex surface. The 
anterior surface bears four transverse lines which terminate on each side in four 
anterior sacral foramina. The anterior primary rami of the first four sacral nerves 
emerge from the anterior sacral foramina. The posterior surface is convex and in 
midline runs a bony ridge, the median sacral crest with 3 or4 rudimentary 
spinous processes. The lamina of the 5th and sometimes the 4th sacral vertebra 
fuse fail to fuse in the midline and thus the deficiency, formed is known as 
“sacral hiatus”. The lateral margins of this space each bear a prominence called 
“sacral cornu” which represents the inferior articular process of the 5th sacral 
vertebra. (Figure1) 
Sacral canal 
 It is a prismatic cavity running throughout the length of the bone and 
following its curves. Superiorly, it is triangular in its section and is               
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Anatomy of sacrum and hiatus 
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continuous with the lumbar epidural space. Its lower limit is the  sacral 
hiatus closed by posterior sacrococcygeal membrane. Fibrous  bands may be 
present in the canal and divide the epidural space into  loculi which prevent the 
spread of solution and these may account for occasional incomplete anaesthesia.  
Contents of the sacral canal 
Sacral and coccygeal nerve roots with their dorsal root ganglia. 
The filum terminale which is the continuation of piameter. 
Epidural plexus of veins formed by the lower end of vertebral veins.  
These vessels are numerous in the anterior aspect than the posteriorly. 
Loose areolar and fatty tissue, which is more dense in males than in females. 
 
Sacral  hiatus 
 
This is a triangular opening present in the posterior wall of the sacrum 
resulting from lack of fusion of the laminae of 5th and may 4th sacral vertebral 
arches. Its apex is at the level of the spine of 4th sacral vertebra. In some cases 
the apex is at the level of 3rd sacral spine due to the absence of the 3rd and 4th 
laminae and occasionally the whole of the bony posterior wall is deficient. 
When the laminae of the 5th sacral vertebra are present, the hiatus may be very 
small with a diameter as narrow as 2mm. The hiatus is covered by the 
sacrococcygeal membrane and pierced by the coccygeal nerves and the 5th 
sacral nerve. This membrane may be ossified in elderly subjects making the 
introduction of caudal needle difficult. 
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       When local anaesthetic is injected into the sacral canal, it ascends 
upwards in the sacral epidural space for a distance proportional to the volume of 
the solution, force of injection, amount of leakage through the eight sacral 
foramina and the connective tissue in the space. 
CAUDAL ANAESTHESIA 
Selection of equipment: 
Reliability of the technique and the incidence of complications largely 
depend on the characteristics of the needle used. The four important 
characteristics of the needle are – bevel, internal &external diameter,  length, 
presence of  the stylet. 
Sharp bevelled needle: 
Advantage – traverse easily through the tissues 
Disadvantage 
¾ Characteristic “give way” while puncturing sacrococcygeal membrane  
may not be clearly felt with sharp needles. 
¾ Sharp needles have long bevel which may have to be advanced further 
into the epidural space so that it lies entirely within it. 
¾ Cartilaginous sacrum can be easily traversed by a sharp and long 
bevelled needle that may lead  to rectal puncture or iliac vessel puncture.  
¾ Straight tipped needle with a bevel of 45-60 degree is ideal for caudal 
epidural anaesthesia. 
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Diameter: 
Small needles may bend & break during procedure 21G, 22G, 23G are 
ideal because it is rigid and large enough to allow reflux of blood or CSF. 
Length: 
Proximity of dural sac makes it dangerous to use very long needles. The 
distance between skin and epidural space is almost always less than 20mm even 
in adults. So it is not advisable to use a needle longer than 30mm.Needle with 
stylet if used prevents formation of an epidermoid tumour due to skin tag. 
Epidural needle with 20G, 21G and 22G are employed  when one intends to use 
an epidural catheter via caudal route to achieve anaesthesia at higher level after 
radiographic confirmation. 
Determination of the volume of local anaesthetics: 
Height of block – depends on the volume injected 
Formula based on weight/ age: 
Armitage formula 
High sacral – 0.5 ml/kg 
High lumbar – 1ml/kg 
Thoracic level – 1.25ml/kg 
Sclhute-Steinberg formula ( 8-12 years) 
0.1ml /segment/ year <7years. 
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Weight is the best predictor. To calculate the total volume to be injected. 
Volume required in ml = 0.65 X number of segments to be blocked x body 
weight (kg) 
Spiegal formula: 
Total volume of injection (ml)= 4+(D-15)/2,Where D is the distance 
between from the spinous process of 7th cervical vertebra to the sacral hiatus in 
cm. 
Modified Spiegal formula: 
Volume of injection (ml) = 4+(D-13)/2 
Despite larger volumes of local anaesthetics used in children as compared 
to adults, peak plasma levels of the local anaesthetics in children remain far 
below the toxic levels than in adults. As the child grows space become less 
compliant and hence large volume can cause high spread of solution and an 
increase in the CSF concentration. 
Maximum volume recommended for injection is 20ml. 
Patient position: 
Three positions can be used for caudal anesthesia; 
1.  Prone position - Most often chosen in adults. 
2.  Lateral decubitus position – This is the most commonly used position in 
paediatric age group. The lateral decubitus position is used in children 
because it is easier to maintain a patent airway in this position than in the 
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prone    position and the landmarks are more easily palpable than in 
adults. 
3. Knee-chest position – This is infrequently used.  
Anatomical landmarks: 
                    
    Classically hiatus is described as the apex of the triangle  formed by 
joining the two posterior superior iliac spine and tip of the coccyx. (fig 2&3). 
The point of puncture is at the midpoint of this triangular space. 
Intergluteal fold is not an ideal landmark because it will not always correspond 
to the midline. Left forefinger is  placed in  coccyx tip,the  hiatus corresponds to 
the second crease of the finger palpation of  this membrane gives a 
characteristic feel of a membrane under tension  similar to that of a fontanelle.  
TECHNIQUE 
Area was  prepared with antiseptic solution. Sterile drapes are placed 
around the site. The skin is punctured with the needle perpendicular and the 
bevel parallel to the sacrococcygeal membrane’s long fibres Once needle 
crosses the sacrococcygeal membrane, a “give way” is felt after which make an 
angle between 20 to 30 degree to the skin. This is done to prevent the needle 
hitching against the anterior aspect of sacrum .The needle is advanced 2-3mm. 
so as to ensure that the entire needle bevel  within the sacral canal. 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 2 caudal technique. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: caudal technique. 
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CONFIRMATION OF SPACE 
Whoosh test: 
It is done by injecting air via the needle and another person should 
auscultate just proximal to the injection site. If the needle is correctly positioned 
in the caudal space, then the characteristic whoosh sound is heard when air is 
pushed. 
Swoosh test 
If the needle is correctly positioned in the caudal space, while injecting 
local anaesthetics, Swoosh sound is heard at a site just proximal to the hiatus. 
It is suggested to avoid injection of air in children as it may cause  patchy 
block and in a rare complication of pneumocephalus ,venous air embolism may 
also occur. 
Other techniques commonly used to identify the space are: 
• Easy injection of drug 
• No resistance to injection 
• No subcutaneous bulge 
INJECTION OF DRUG: 
After gentle asipration the drug is injected over a period of 60-90seconds. 
Irrespective of the speed injected (0.023-0.33ml/sec) syringe should be 
repeatedly aspirated during the course of injection. The patient is monitored for 
any change in Mean arterial pressure /heart rate. Faster injection causes 
increased cephalad spread resulting in higher block and respiratory problems. 
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Transient increase in intracranial pressure with transient loss of consciousness 
and headache can occur .On the other hand, too slow an injection increases the 
chance of lateralisation of the block or a lower level of anaesthesia as the drug 
tends to leak through the foramina and increases the risk of needle 
displacement. 
INDICATIONS: 
Ideal for lower abdominal and lower limb surgeries 
Emergency: testicular torsion, strangulated hernia repair, paraphimosis, 
wound debridement of pelvis/ lower limbs. 
Elective: 
Repair of inguinal hernia, umbilical hernia, hydrocele, Orchidopexy, 
anorectal, genitourinary surgeries, pelvic, hip, phimosis and lowerlimb 
surgeries.  
CONTRAINDICATIONS: 
a) Hydrocephalus.  
b) Seizure disorders.  
c) Vertebral osteosynthesis. 
d) Local skin infection.  
e) Pilonidal sinus near hiatus. 
f) Major sacral malformation –meningomyelocele. 
g) Meningitis. 
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COMPLICATIONS 
Possibilites due to error in the technique: 
1. Subcutaneous injection. 
2. Vascular puncture: 10-15%. Since epidural veins are valveless, 
injection may be immediately followed by convulsions, arrhythmias, 
hypotension and respiratory depression. 
3. Dural puncture: If dura is punctured, withdraw the needle immediately. 
Second attempt  can be made provided the drug is injected slowly 
under low pressure. 
4. Subarachnoid injection may lead to total spinal even along cranial 
nerve distribution. 
5. Bone marrow, rectal and intraosseous injection 
6. Complete or partial failure of the block More common in > 7 years old. 
7. Lateralization: occurs in 1 in 1000 cases When caudal is performed in 
lateral decubitus, 50% have a level of anaesthesia 2 dermatomes higher 
on the dependent side Slow injection may cause a difference of more 
than 4 dermatomes ; may be due to presence of a complete plica 
mediana dorsalis. 
8. Un anaesthetised dermatomes. 
9. Large size dermatomes like L5- S1 missed. 
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10. Neurological complications Urinary retention – most common if 
narcotics are used in caudal. Time to micturate may be delayed but not 
troublesome 
11. Nerve injury is rare. 
12. Other complications Vomiting, epidural infection , meningitis, 
shivering. 
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5. PHYSIOLOGICAL CONSIDERATION 
Classification of sensory fibers 
Sensory fibres Speed of transmission Sensory function Myelination 
C fibres  0.5 -2m/sec Pain,cold, heat, touch. Unmyelinated 
A-Alpha 
fibres 70 -120m/sec 
Noxious chemical 
thermal, mechanical 
stimuli  
 
Myelinated 
A-Beta fibres 30 -70m/sec 
Light touch, 
pressures,vibration 
proprioception 
 
Myelinated 
A-Gamma 
fibres 
30-70m/sec 
Proprioception, 
Motor to muscle 
spindle 
Myelinated 
A-Delta fibres  12 -30 m/sec Pain, cold, touch Myelinated 
B fibres  3 -15 m/sec 
Pre ganglionic 
autonomic 
(sympathetic) 
Myelinated 
 
PAIN PATHWAYS   
 
Pain receptors consist of peripheral plexus of unmyelinated nerves, 
activated by high-intensity stimuli which may be thermal, mechanical,  
electrical or chemical. Pain is conducted along two types of fibres in the 
periphery, A delta fibres are finely myelinated and relatively rapidly conducting 
(12-30 m/sec). They conduct the sharp pain produced by pin prick or electrical 
stimulation as well as thermal stimuli and responsible for withdrawal reflex.      
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A delta conducted pain is felt quickly and is well localised. ‘C’ fibres are very 
fine non-myelinated fibres which conduct at a very slow rate 2-3m/sec or less. 
Their threshold for stimulation is higher and is responsible for delayed and truly 
noxious burning or throbbing pain. 
The activation of two different type of fibres (A delta &C) by noxious 
stimuli explains the double sensation for pain evoked in the human by a single 
short noxious stimulus, rapid pricking pain(0.1sec, latency, fast pain) carried by 
A delta fibres is followed approximately one second later by a burning pain 
(slow pain) mediated by C fibres.  
Peripheral sensory nerves have their cell bodies in the dorsal root 
ganglion and the central projection of A delta and C fibre neurons enter the 
dorsal horn in the lateral division of the dorsal root. 
             
 
 
 
 
 
 
 
Figure 4 :Spinalcord laminae 
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In the grey matter of the spinal cord cell bodies are arranged in a 
series of laminae, some of which have classical names but which are more 
simply given roman numerals by Rexed, starting with I at the tip of the 
dorsal horn. A delta and C primary afferent fibres terminate principally in 
the marginal layer (lamina I)   and the substantia gelatinosa (lamina II)  of 
the spinal cord (fig.4). Some of the neurons of the lamina I which synapse 
with A delta fibres, give off axons which ascend in the contralateral 
anterior columns without synapsing with neurons from deeper layers. The 
majority of the pain fibres, however synapse in the substantia gelatinosa 
into intermediate neurons which sent projections to deeper layers or with 
the dendrites of neurons whose cell bodies reside in deeper layers, 
principally in lamina V.  
The central projection from cell bodies in lamina IV, V & VI with 
contribution from lamina I, cross midline in the anterior commissure to form the 
spinothalamic tract, which ends in thalamus, principally in the ventroposterior 
nucleus, sending a few fibres  enroute  to the  periaqueductal grey matter. The 
ventroposterior nucleus of the thalamus projects to the post central gyrus, the 
sensory cortex.  
Pain stimuli can also pass via interneurons to cell bodies in the  
intermediate grey matter (laminae VII & VIII) whose central projections  also 
ascend in the contralateral anterolateral columns, forming  
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Spinothalamic Pathway 
While it appears that the thalamus is involved in the experience of  
pain, the post-central gyrus is necessary for its accurate localization and 
prefrontal cortex for unpleasant affective reactions to it. 
INHIBITORY PATHWAYS: 
1. Large primary afferent fibres, which mainly ascend in the dorsal columns 
and whose cell bodies lie in the dorsal root ganglion send collaterals to 
synapse with and activate inhibitory inter neurons in the dorsal horn. These 
inturn inhibit release of transmitters  along pain pathways. Thus, 
stimulation of large A beta cutaneous afferents may inhibit pain 
transmission (gate theory of Melzack and Wall).  
2. Inhibitory fibres, which descend in the dorsolateral white funiculus and 
whose cell bodies lie in the medullary raphe nuclei, may also inhibit pain 
transmission  presumably by an action of the inhibitory interneurons. 
Activity in these descending inhibitory fibres may be provoked by  
stimulation of the cell bodies in the medulla directly or of the  
periaqueductal grey matter. 
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PHYSIOLOGICAL CHANGES 
While activity in sensory neurons may be excited in the periphery by 
thermoreceptor, nociceptor or mechanoreceptor stimulation  cell bodies in the 
posterior horn are responsive to different intensities of stimulation. Thus certain 
cells found principally in lamina IV respond only to a low intensity of 
stimulation such as light touch. These are termed low threshold or LT cells. 
They respond maximally to low- threshold stimuli and do not increase their 
firing rate with increased stimulus intensity. They are therefore incapable of 
conducting pain. Another type of cell, found principally in lamina V responds 
over a wide range stimulus intensities, the so called wide-dynamic range or 
WDR cells. Noxious stimuli can excite a variable response in WDR cells in 
lamina V, a third type of cell is responsive to stimuli only within the noxious 
range. Such cells are known as High threshold cells or HT cells and are found 
mainly in lamina I. A delta and C fibre stimulation in the periphery results in 
increased firing in HT and WDR cells in lamina I and V which is conducted up 
in spinothalamic tract. (Fig 5) Surgery produces local tissue damage with 
consequent release of algesic substances like prostaglandins, histamine, 
serotonin, bradykinin, hydroxytryptamine, substance P and generation of 
noxious stimuli that are transduced by nociceptors and transmitted by A delta 
and C fibres to the neuraxis. 
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Figure 5: Gate control theory. 
 
        L.glutamate is the only excitatory aminoacid which is concentrated 
in the dorsal horn. There are a number of receptors for glutamate namely 
NMDA (N methly D aspartate), AMPA (α amino3 hydroxy 5 methyl- isoxazole 
4 propionate), L-2 amino-4-phospono butyrate(LAP4), kainite and metabotropic 
receptors. The majority of the opioid receptors in the dorsal horn are mu 
receptors although delta and kappa receptors are present.  
Segmental reflex responses associated with surgery includes increased 
skeletal muscle tone and spasm with associated increase in O2 consumption and 
lacticacid production. Stimulation of sympathetic neuron causes tachycardia, 
increased stroke volume, cardiac work and myocardial oxygen consumption. 
Suprasegmental reflex responses result in further increase in sympathetic tone 
and hypothalamic stimulation, metabolism and increased O2 consumption. 
Hence the most obvious motive for relieving postoperative pain is not only 
humanitarian but also to contribute a more  rapid and complete postoperative 
recovery. 
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6. APPLIED PHARMACOLOGY 
A. PHARMACOLOGY OF ROPIVACAINE 
 
Ropivacaine is the new amino amide local anaesthetic. It is a derivative 
of pipecoloxylidide. Pipecoloxylidide was first synthesized in 1957. 
Pipecoloxylidide are chiral drugs due to asymmetric carbon atoms and form two 
groups of S and R enantiomers.  Ropivacaine is a pure S enantiomer with chiral 
purity of  99.5%. Ropivacaine is prepared by alkylation of S enantiomer of 
dibenzoy-l-tartaric acid 
PHYSIOCHEMICAL PROPERTIES: 
Chemical name as S-1-propyl-2,6- pipecoloxylidide hydrochloride 
monohydrate. (Figure 6) 
 
 
 
   
 
Figure6: Chemical structure of Ropivacaine 
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Molecular weight - 274 
Pka -  8.07 
 pH -  7.4 
Protein binding -  94% 
Partition coefficient (lipid solubility)   -   8.7 
Mean uptake ratio -  94 
T1/2  -         111 minutes, 
Clearance  -  10.3 L/minutes. 
Solubility in H2O at 250C -          53.8g/L 
Specific gravity -          1.002 to 1.005 at 25oC. 
MECHANISM OF ACTION:    
Ropivacaine acts through inhibition of sodium channel. It inhibits the 
conduction of sodium ions through the channel and also potassium channel. 
Thus it blocks the generation and conduction of impulses across the nerve 
fibres. This type of block is reversible.  
PHARMACOKINETIC PROPERTIES: 
Absorption 
The plasma concentration of ropivacaine is dependent on many factors 
like route of administration, dose of drug administered, concentration of drug 
used, vascularity of the region and hemodynamic status of patient. It shows the 
biphasic absorption phase from the epidural space. The mean half life is 14 
minutes in first phase and 4 hours in second phase. The rate limiting factor is 
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the slow absorption from the epidural phase. Thus it has longer duration of 
action through the epidural route.  
Distribution 
The steady state plasma concentration after intravascular injection is 
about 59+7 liters in total volume of distribution. The protein bound fraction is 
about 94%. It mainly binds to α–1- acid glycoprotein. There is an increase in 
bound form of drug in post operative state due to increase in α-1-acid 
glycoprotein from stress response in surgery. This is especially so after 
continuous epidural infusion. Ropivacaine can easily cross the placenta and 
equilibrium is reached. 
Metabolism 
Ropivacaine is extensively metabolized in the liver. It is predominantly 
metabolised by aromatic hydroxylation involving cytochrome P4501A to          
3-hydroxy ropivacaine. About 37% of the total dose is excreted in urine. It is 
excreted in both free and conjugated form of 3-hydroxy ropivacaine. There is a 
low concentration of 3-hydroxy ropivacaine in the plasma. Another metabolite, 
2-hydroxymethyl - ropivacaine has been identified but is not quantified in the 
urine. 3-OH-ropivacaine and N-de-alkylated metabolite of ropivacaine are the 
major metabolites excreted in the urine. These are especially formed during the 
continous epidural infusion. There is no reacemerization between the S and R 
forms in the body.  
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Elimination 
Ropivacaine is mainly eliminated through the kidney as various 
metabolites.About 86% of the total drug is excreted through the kidneys. The 
total clearance is about 387 ml/min. The mean half life is about 1.8 hours after 
intravascular injection and about 4.2 hours after epidural injection. 
PHARMACODYNAMIC PROPERTIES: 
Action on Nervous system 
The type of blockade produced by ropivacaine depends upon the 
concentration of drug used. In low concentration it blocks both Aδ and C fibres 
which is more potent than that of equal concentration of bupivacaine. In high 
concentration, the blockade of Aδ fibres’ is less than that of bupivacaine while 
the blockade of C fibres is similar. The penetration of ropivacaine into myelin 
sheath is less due to low lipid solubility compared to bupivacaine. Thus it 
preferentially blocks C fibres than Aδ fibres. This causes less potent motor 
blockade.   
The addition of epinephrine does not influence the type of blockade 
produced. In toxic doses, it causes initial excitation of nervous system 
manifesting as restlessness, tremor, and convulsions. Later it leads to depression 
of medullary centre and coma. 
Effect on Cardiovascular system 
The effects are mostly due to blockade of sympathetic fibers. There is 
decreased venous return and decreased heart rate which produces hypotension. 
26 
 
Effect on respiratory system 
Ropivacaine does not have any marked effect on the respiratory system in 
normal doses. Higher doses leading to toxicity of drug produces respiratory 
depression secondary to medullary depressant effect. 
INDICATIONS 
Surgical anaesthesia: 
a) Spinal anaesthesia. 
Epidural anaesthesia. 
Caudal anaesthesia. 
Peripheral nerve block and infiltration anaesthesia. 
Pain management: 
a) Labour analgesia – intermittent bolus or continous infusion  
a. more in  walking epidurals 
Post  operative  pain management – epidural infusion as 
i. Intermittent bolus. 
ii. Continous infusion. 
iii. Patient controlled analagesia. 
Pain management in paediatrics: 
a) Caudal epidural block. 
b) Peripheral nerve block for intra and postoperative pain management. 
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CONTRAINDICATIONS 
a) Known cases of allergic reactions to amide type of local  anaesthetics. 
b) Intravenous regional anaesthesia (Bier’s block).  
c) Obstetric Para cervical anaesthesia.  
d) Hemodynamic instability. 
e) Septicemia. 
f) Local site infection. 
ADVERSE EFFECTS 
The adverse reactions to ropivacaine are related to excessive plasma 
levels due to excess dosage, unintentional intravascular injection or slow 
metabolic degradation. The mean doses of plasma level when toxicity begin to 
occur are  about  4.3 and 0.6 μg/ ml of total and free plasma concentrations 
respectively. The toxic levels are reached in cases of continuous epidural 
infusion as the drug is administered for long times.  
THE VARIOUS POSSIBLE SIDE EFFECTS : 
g) Cardiovascular System – bradycardia, hypotension, vasovagal reaction, 
syncope, arrhythmias. Due to low lipid solubility the cardiotoxic potential 
is less than that seen with bupivacaine. 
h) Central and peripheral nervous System – dyskinesia, hypokinesia, 
neuropathy, vertigo, tremors, paresis, neropathy and coma.  
i) Gastrointestinal System - nausea and vomiting, incontinence, tenesmus. 
j) Hearing and Vestibular - tinnitus, hearing abnormalities.  
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k) Hepato - Biliary System – jaundice  
l) Musculoskeletal System – myalgia.  
m) Psychiatric Disorders - agitation, confusion, nervousness, amnesia, 
hallucination, emotional liability, insomnia, nightmares. 
n) Skin Disorders - rash, urticaria. 
o) Urinary System Disorders- urinary incontinence, micturition disorder. 
p) Vascular - deep vein thrombosis, phlebitis, pulmonary embolism. 
AVAILABILITY 
Ropivacaine is available in ampoules of isobaric solution in concentration 
of 0.2%, 0.5%, 0.75% and 1%. The solutions are prepared in preservative free 
form. 
DOSAGES 
a) Caudal    - 1ml/kg of 0.2% solution. 
b) Epidural - 15 to 20 ml of 0.2% or 0.5% solution. 
c) Spinal     -   3 to 4ml of 0.5% or 0.75% in adults. 0.3 to 0.5mg/kg of 0.5% 
solution in children. 
d) Peripheral nerve block – 15 to 30 ml of 0.15% to 0.5%. The toxic level is 
reached when more than 2mg/kg of drug volume is used.  
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B. PHYSIOLOGY OF α2-ADRENOCEPTORS 
α2 - receptors are found in many sites throughout the body. α2 
adrenoceptors are found in peripheral and central nervous systems. It is also 
present  in effector organs such as the liver, kidney, pancreas, eye vascular 
smooth muscles and platelets. Physiologic responses mediated by  α2 adreno-
ceptors vary with location and can account for the diversity of their effects. 
The classification of α2 - receptors based on anatomical location is 
complicated since these receptors are found in presynaptic, postsynaptic and 
extrasynaptic locations. α2 - adrenoceptors are divided into three subtypes; each 
subtype is responsible uniquely for some of the actions of α2 - receptors. (Fig 7) 
α2A    is the predominant subtype in CNS and responsible for the  
sedative, analgesic and sympatholytic effect.  
α2B is found mainly in the peripheral vasculature and responsible    
for the short-term hypertensive response. 
α2C is found in the CNS and  responsible for the anxiolytic effect. All 
the subtypes produce cellular action by signaling through a G-protein which 
couples to effector mechanisms. This coupling appears to differ depending on 
the receptor subtype and location. The α2A-adreno-ceptor subtype seems to 
couple in an inhibitory fashion to the calcium channel in the locus ceruleus of 
the brainstem, whereas in the vasculature the α2B-adrenoceptor sub type couple 
in an excitatory manner to the same effector mechanism. 
 
 
 
 
 
 
Figure 7: Alpha 2adrenergic receptors 
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C.  PHARMACOLOGY OF CLONIDINE HYDROCHLORIDE 
 
                           
       
                 
 
 
 
 
 
 
 
Figure 8. Chemical  structure of clonidine hydrochloride. 
Introduction:   
Clonidine hydrochloride is a centrally acting selective partial alpha 2 
agonist introduced in early 1960s.It was initially used as a nasal decongestant 
.Its anti hypertensive property was found out after that. Subsequently more 
insight into the pharmacological properties has led to its use in clinical 
anaesthesia practice as well.(Fig 8) It is an imidazoline compound and exists as 
a mesomeric compound. The chemical name is 2-(2,6- dichlorophenylamino)-2 
imidazoline  hydrochloride.  The structural formula is C9H9CL2N3HCL. The 
molecular weight is 266.56.  Clonidine is an odourless, bitter, white, crystalline 
substance soluble in alcohol and water. Clonidine improves the quality of  
anaesthesia  provides a more stable cardiovascular course during  anaesthesia 
presumably because  of their sympatholytic effect and  need for lower dose of 
cardio active anaesthetic and reduces the dose  requirement of the anaesthetic  
agent. Clonidine reduces the halothane MAC by up to 50% in a dose dependent 
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manner. Clonidine potentiates the anaesthetic action of the local anaesthetics 
with fewer side effects in peripheral nerve blocks and central neuraxial 
blockade. 
Availbility: 
Available as one ml ampoule containing 150 micrograms. It should be 
stored below 25 degree Celsius. It also available as tablet. 
Mechanism of action: 
Clonidine is a centrally acting partial α2 adrenergic agonist with a 
selectivity ratio of 220: 1 in favour of α2 receptors.When clonidine was injected 
into epidural space it is penerates the blood brain barrier and reaches to the 
hypothalamus and medulla. It is stimulates the inhibitory α2 adrenergic 
receptors to reduce the central neural transmission in the spinal neurons. 
The α2 adrenoreceptors are densely found in the locus ceruleus, whch is 
an important source of sympathetic nervous system innervation of the forebrain 
.Clonidine is an inhibitor of pontine locus ceruleus as it stimulates the α2 
adrenergic neurons in the medullary vasomotor centre, which reduces the 
sympathetic nervous system outflow from central nervous system to peripheral 
tissues. The sympathetic nervous system outflow reduction is caused by 
peripheral vaodilatations and leads to decrease the blood pressure, heart rate and 
cardiac output. 
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Clonidine reduces the anaesthetic requiremet and its analgesic effects  
due to modification the potassium channels in the central nervous system and 
hyperpolarisation in the cell membranes. 
Clonidine is neuraxial inhibits of spinal substance-P release is believed to 
be involved in the analgesic effect. Another contribution to analgesic effect may 
be through the release of acetylcholine in the neuraxial region. The α2 
adrenergic agonist also enhances analgesia from intraspinal opioids. Sedation is 
produced by its action on locus ceruleus. 
The α2 adrenoreceptors terminals are presented centrally, peripheraly, 
superficial laminae of the spinal cord and brain stem neuclei is believed to 
involved analgesic effects after neuraxial administration of clonidine.it also 
reduce the cold response threshold and increase the sweating threshold may 
inhibition of the shivering response. 
Clonidine affects the blood pressure in a complex fashion after neuraxial 
or systemic administration because of the opposing action at multiple sites. In 
the nucleus tractus solitories and locus ceruleus of the brain stem, activation of 
post-synaptic α2 adrenoreceptors decrease the sympathetic actions.  producing 
hypotension and anti- arrythmogenic action. 
In peripheral nerves it produces a minor degree of blockade at high 
concentrations with some preference for C- fibres and this effect in part enhance 
the peripheral nerve block when added to local anaesthetics, probably because 
the α2  adrennoreceptors are lacking on the axons of peripheral nerves. 
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Pharmacokinetics: 
Clonidine well absorped from orally and bioavailability of clonidine is 75 
to 95%. It is peak plasma half life is 60 to 90 minutes, Plasma half life is 12 to 
33 hours.50% of the drug is mainly metabolized in the liver  whereas it is 
excreted in an unchanged form by the kidney 40 to 60%, and its half life can 
increase in the presence of renal dysfunctions. A transdermal delivery system is 
available in which the drug is released at a consant rate for a week. Three or 
four days are required to achieve steady state concentration. 
After 300µgm/ kg intravenously infused over 10 min produces: 
Distribution t½: 11± 9 minutes 
Elimination t½:  9± 2 hours, 41 hours in severe renal dysfunction. 
Volume of distribution: 2.1± 0.4 l / kg 
Plasma protein binding: 20 - 40% in vitro.  
DOSAGE REGIMEN: 
Oral: 3-5μg/kg. 
Intramuscular: 2 μg/ kg. 
Intravenous: 1-3μg/kg. 
Spinal: 50 -100μg. 
Caudal: 1-2μg/kg. 
Epidural: 1-2μg/kg. 
Transdermal: 0.1-0.3 mg released per day. 
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PRECAUTIONS: 
1. In renal insufficiency patients, lower dose is needed. 
2. Sudden withdrawal of prolonged continuous epidural infusion roduces 
hypertensive crisis. So gradually discontinue over 2 to 4 days to prevent 
this complication. 
3. Use with caution in patients with cerebrovascular or coronary 
insufficiency. 
4. Patient on beta blocker therapy,beta blocking drugs should be withdrawn 
several  days before the epidural clonidine. 
CONTRAINDICATIONS: 
1. Known hypersensitivity to clonidine or components of the product. 
2. Brady arrhythmia or AV block. 
3. Severe cardiovascular disease. 
4. Cardiovascular / hemodynamic instability. 
INTERACTIONS: 
1. Clonidine may potentiate the CNS- depressive effect of alcohol,  
barbiturates or other sedative drugs.  
2. Clonidine potentiate the hypotensive action with narcotic drugs.  
3. The hypotensiveeffects of  the clonidine is antagonized by tricyclic 
antidepressant. 
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4. Concomitant administration of drugs with a negative chronotropic or 
dromotropic effect (beta blocker, digoxin) can cause or potentiate 
bradycardia and rhythm disturbances. 
5. Beta blockers may potentiate the hypertensive response seen with 
clonidine withdrawal. 
USES: 
1. Caudal anaesthesia: 1to2μg/kg of clonidine combined with local 
anaesthetic agents prolong the duration of analgesia by 2 or 3 times without 
hemodynamic side effects. 
2. Epidural block: Clonidine as sole agent or in combine with opioids or local 
anaesthetics to provide excellent analgesia in labour analgesia.  
3. Spinal anaesthesia: Clonidine combined with local anaesthetics improves 
the quality and duration of the block, minimize the tourniquet pain during 
lower limb surgery, and prevents shivering. 
4. Pre anasthetic medication : Oral clonidine is 5 micg/kg. 
a. Blunts reflex tachycardia associated with direct laryngoscopy for 
intubation of trachea. 
b. Reduce the intraoperative instability of the blood pressure and heart rate. 
c. Plasma catecholamine concentrations levels decreased. 
d. Dramatically decrease anaesthetic requirements of inhaled and injected 
drugs.  
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5. In Peripheral nerve blocks: Clonidine prolongs the duration of anaesthesia 
and analgesia with local  anaesthetics by two times  in a dose of 75 to 150 
micro grams.  
6. In Bier’s Block: 150 microgram of clonidine enhances the tolerance of 
tourniquet. 
7. It is also used in intra articular analgesia. 
8. Protection against perioperative myocardial ischemia: 
Clonidine decreases myocardial ischemia, infarction and mortality     
following cardiovascular surgery. 
9. In the management of hypertensive crisis clonidine is useful. 
10. Treatment of shivering; Administration of clonidine75μg IV abolishes 
shivering by inhibiting thermoregulatory control. 
11. Clonidine is useful in the treatment of opioid and alcohol withdrawl 
syndrome. 
Side effects; 
1. The most common side effects are sedation and xerostomia. 
2. Cardiovascular complications are bradycardia, hypotension, and sinusnode 
arrest,  junctional  bradycardia, high degree AV block and other arrhythmia 
are reported rarely. Occasionally bradycardia may requires treatment with 
I.V anticholinergics.Orthostatic hypotension occurs rarely. 
3. Rebound hypertension; Abrupt discontinuation of clonidine can result in 
rebound hypertension as soon as 8 hours and as late as 36 hours after the 
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last dose. Symptoms of the rebound hypertension are headache, abdominal 
pain, tachycardia, nervousness, and diaphoresis, which often precede the 
actual increase in systemic blood pressure. Labetalol is useful in the 
treatment of rebound hypertension. 
4. Skin rashes occur frequently. 
5. Impotence occurs occasionally. 
Treatment for over dosage: 
There is no specific antidote for clonidine over dosage. Measures like 
atropine, ephedrine, and i.v. fluids are enough  in the management.Yohimbine 
partially reverses the analgesia and sedation but not the blood pressure and heart 
rate changes produced by the epidural  clonidine. 
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D.  PHARMACOLOGY OF DEXMEDETOMIDINE 
Dexmedetomidine is an α2 adrenergic agonist. The α2adrenergicreptors 
agonists produce sedation, anxiolysis, hypnosis, analgesia, and sympatholysis.It 
is a nonselective α2 agonist with a 1600 greater selectivity for α2 receptor as 
compared to  α1 receptor. Introduced in clinical practice 1999 and approved by 
FDA only for short-term, less than24 hours sedation and analgesia for  ICU  
adult patients. Now a days used off-label outside of the ICU for sedation, 
adjunct analgesia, sedation for short term diagnostic procedures. It decreases the 
sympathetic tone and also attenuates the stress response during intubation and 
surgery. They are also used as adjuvants during intravenous regional 
anaesthesia.    
Physicochemical Characters:-  
It is a potent, highly selective α2 adrenergic agonist. Its freely water 
soluble. Molecular formula is C13H16N2.HCl. 
Molecular weight: 236.74. 
The chemical name as 4-(S)-[1-(2,3dimethylphenyl)ethyl]-1H-imidazole 
monohydrochloride. 
It is a d-enantiomer of medetomidine. This substance has been used for 
sedation, hypnosis and analgesia in animal science for many years. It has high 
ratio of specificity for the α2 receptor compared with clonidine. 
vessels
release
cord. I
and an
           
          
 
 
F
MECH
recepto
helices
adenyl
channe
Postsynap
 produce
 of norep
The α2 ad
t inhibits 
algesia. (F
               
igure:9. 
ANISM
α2 adreno
rs, which
.α2 adre
cyclase, w
ls and thu
 
 
tic α2 adr
 vasocon
inephrine 
renorecep
the neuro
igure.9) 
     
Chemical
 OF ACT
receptors
 contains
nergic re
hich in 
s augmen
enorecept
striction. 
and leads
tors also 
nal firing
 structur
ION 
 belongs 
 a charac
ceptors 
turn  inh
ts the hyp
39 
 
ors which
Presynap
 to fall in 
located in
, causing 
e of dexm
 
to the la
teristic st
activation
ibits the 
erpolariz
 are locat
tic α2 ad
blood pre
 central n
hypotensi
edetomid
rge fami
ructure o
 are th
opening 
ing potass
ed in the 
renorecep
ssure and
ervous sy
on, brady
ine hydr
ly of G 
f seven tr
e decrea
of voltag
ium ion c
periphera
tors inhi
 heart rate
stem and
cardia, se
ochloride
protein c
ansmemb
sed activ
e gated c
hannel ac
l blood 
bit the 
. 
 spinal 
dation, 
. 
oupled 
rane α 
ity of 
alcium 
tivity.  
40 
 
METABOLISM AND PHARMACOKINETICS  
Dexmedetomidine is 94% protein bound.It undergoes an extensive 
hepatic metabolism. It is rapidly distributed and extensively metabolized in the 
liver by glucuronidation, conjugation, N-methylation, or hydroxylation and 
cytochrome P450 mediated metabolism. Metabolites are excreted in the urine 
(about 95%) and in the feces(4%). Dose needs to be adjusted in patients with 
liver impairment, but dose  need not be adjusted  in renal dysfunction  patients. 
Large doses can produce the vasoconstriction leading to reduced drug volume of 
distribution. 
Dexmedetomidine  follows the nonlinear pharmacokinetics. 
Elimination half life:-  2 to 3 hours. 
Distribution half life: - 6 minutes. 
Volume of distribution (vss):-118 litres. 
Context-sensitive half-time: - Ranges from 4 minutes after a 10-minutes 
infusion to 250 minutes after an 8-hour infusion.  
It has shorter duration of action compared to clonidine. The most 
frequently observed side effects in patients receiving dexmedetomidine  include 
hypotension, hypertension, nausea, bradycardia and atrial fibrillation. 
Dexmedetomidine cannot be used in patients with severe valvular heart 
diseases or ischaemic heart disease, elderly patients, Diabetes mellitus patients, 
Complete heart block as it decreases sympathetic nervous activity. 
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Dexmedetomidine does not affect the synthesis, storage or metabolism of 
neurotransmitters and does not block the receptors, thus providing the 
possibility of reversing the hemodynamic effects with vasoactive drugs or the 
specific α2antagonist, Atipamezole which acts by increasing the central 
turnover of norepinephrine. Its duration of action is 2 hours. 
DOSAGE 
It is available as100 mcg in1 ml ampoule or 2 ml vial. It is containing 
100mcg/ml. It is generally diluted in 50ml  of 0.9% normal saline to obtain 
concentration of 4mcg/ml. 
DRUG INTERACTIONS 
CYP2A6 inhibitors such as isoniazid, methoxsalen, miconazole, may 
increase the level and effects of dexmedetomidine. Conversly may increase the 
levels and effects of CYP2D6 substrates which include amphetamines, selective 
betablockers , lidocaine. Dexmedetomidine may decrease the levels and effects 
of CYP2D6 prodrug substrates, such as codeine, oxycodeine and tramadol. It 
has a weak inhibiting effect on cytochrome P 450 enzymes, so it may lead to 
increased plasma concentration of opioids when used concurrenly. Adverse 
reactions associated with dexmedetomidine such as hypotension, bradycardia 
may be augmented or potentiated by vasodilators and negative ionotropic drugs 
like digoxin and esmolol. 
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ADVANTAGES 
• It is a Sedative and analgesic drug that  produces sympatholysis 
without any respiratory depression. 
• It is also an antisialogogue. 
EFFECTS ON THE CENTRAL NERVOUS SYSTEM  
Sedation  
It produces its effect by acting on the α2 receptors present in the locus 
caeruleus and analgesic effect due to its action on α2 receptors within the locus 
caeruleus and spinal cord. It produces natural sleep with minimal respiratory 
depression. The quality of sedation produced by dexmedetomidine seems 
different compared with that produced by other sedatives acting through the 
GABA systems like benzodiazepines. 
 Patients receiving dexmedetomidine infusions of sedation regimen in  
ICU setting have been described as being very easy to wake up and having the 
ability to follow commands but are able to recall the events in the ICU. It is 
easy to perform the daily wake up tests. In this critical test, mechanically  
ventilated ICU patients are taken off all sedatives to assess their mental status 
and titrate sedation. 
The α2 agonists act through the endogenous sleep-promoting pathways to 
exert their sedative effect. 
 Dexmedetomidine produces a decrease in activity of the projections of 
the locus caeruleus to the ventrolateral preoptic nucleus which in turn leads to 
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increase in  GABAergic and galanin release in the tuberomammillary nucleus, 
producing a decrease in histamine release in cortical and sub cortical 
projections.  
The α2 agonists inhibit ion conductance through L-type or P-type calcium 
channels and facilitate conductance through voltage-gated calcium-activated 
potassium channels. 
Dexmedetomidine can produce profound sedation, and it has been used as 
a total IV anaesthetic when given at 10 times the normal sedation concentration 
range.  
It produces  cerebral protection by decreasing cerebral blood flow without 
affecting  CMRO2, decreases cerebral blood flow velocity. 
It has minimal effect on the cortical evoked potentials. It also ablates 
memory in a dose dependent manner. 
The α2 agonists have the advantage that their effects are readily reversible 
by α2-adrenergic antagonists (e.g., atipamezole). It is administered in the dose of 
50µg/kg I.V. 
Atipamezole is not currently approved for human use. Similar to other 
adrenergic receptors, the α2 agonists also show tolerance after prolonged 
administration. 
Dexmedetomidine can also be used for addiction treatment, rapid opioid 
detoxification, cocaine withdrawal, and iatrogenic induced benzodiazepine and 
opioid tolerance after prolonged sedation. 
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Analgesia:- 
When dexmedetomidine is injected into the epidural space, it rapidly 
diffuses into the CSF. The effects on blood pressure are slower in onset with an 
epidural injection than with an intrathecal administration. Onset of action via 
epidural route is 5 to 20 minutes. The primary site of analgesic action is thought 
to be at the spinal cord. It produces prolonged analgesia and increased duration 
of sensory and motor blockade when administered intrathecally along with 
bupivacaine. 
RESPIRATORY EFFECTS:- 
Dexmedetomidine throughout a broad range of plasma concentration has 
minimal effects on the respiratory system. Co administration of 
dexmedetomidine with other sedatives, hypnotics or opioids is likely to cause 
additive effects. It decreases the minute ventilation in a dose dependent manner. 
At lower concentrations, no effect on arterial oxygenation and pH. With 
increasing concentration, increased respiratory rate is observed. 
CARDIOVASCULAR EFFECTS:- 
No rebound hypertension is observed as compared to clonidine. It 
decreases the myocardial oxygen consumption; there is increased redistribution 
of blood from non ischaemic zone to ischaemic zone. It leads to increased flow 
in epicardial and endocardial vessels. 
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PERIOPERATIVE USES OF DEXMEDETOMIDINE 
A. Premedication 
Dexmedetomidine is   anxiolytic, sedative, analgesic, antisialogogue and 
sympatholytic   properties, which makes it suitable as a premedication agent. 
Dexmedetomidine   decreases the thiopentone(30%) dose requirement, 
decreases the haemodynamic response to intubation, decreases volatile 
anaesthetic requirement .It should be administered at a dose of 0.3-0.6µg/kg 
intramuscular injection given 15minutes before surgery The administration of 
intramuscular dexmedetomidine at a dose of 1 μg/kg for premedication in 
outpatient cataract surgery resulted in sedation, and decrease in intraocular 
pressure without significant hypotension or bradycardia. Also the administration 
of dexmedetomidine for premedication decreases oxygen consumption 
intraoperatively by 8% and postoperatively by 17%.  
Indications for the use of dexmedetomidine as premedication include 
patients susceptible to preoperative and peri operative stress, drug addicts and 
alcoholics, chronic opioid users and hypertensive patients. 
B. Intra operative uses of dexmedetomidine 
Intra operative uses of dexmedetomidine include its use as an adjunct to 
general anaesthesia, as an adjunct to regional anaesthesia, in monitored 
anaesthesia care (MAC) or as a sole agent for total intravenous anaesthesia 
(TIVA).  
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1. Used an adjunct to general anesthesia 
The use intraoperative dexmedetomidine may increase hemodynamic 
stability because of attenuation of the stress-induced sympathoadrenal responses 
to intubation,decreased level of plasma catecholamines during surgery and 
during emergence from anesthesia. 
Administration of intravenous dexmedetomidine decreases the narcotic 
consumption intraoperatively and post operatively when compared to propofol. 
It reduces the vasoconstriction and the shivering threshold and is 
associated with a lower incidence of shivering. 
It decreases the muscle rigidity caused by high doses of opioids. It also 
decreases the cardio stimulatory effects and post anaesthetic delirium produced 
by ketamine. 
2. Used for regional anesthesia 
The use of dexmedetomidine as adjuvant in regional anesthesia is 
approved.There is significant prolongation of sensory and motor block as 
compared to bupivacaine  alone. Intrathecal α2-adrenergic agonists produce 
analgesia by depressing the release of C-fiber transmitters and by 
hyperpolarization of post-synaptic dorsal horn neurons. This antinociceptive 
effect may explain the prolongation of the sensory block when added to spinal 
anesthetics.The prolongation of the motor block of spinal anesthetics may result 
from the binding of α2-adrenergic agonists to motor neurons. 
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3. Used in monitored anesthesia care 
Dexmedetomidine confers arousable sedation with ease of orientation, 
anxiolysis, mild analgesia, lack of respiratory depression and hemodynamic 
stability at moderate doses. These properties allow dexmedetomidine to be an 
almost ideal agent for MAC despite its lack of amnesia and poor controllability 
because of its slow onset and offset. 
Dexmedetomidine in MAC was used successfully in many situations: 
when patient arousability needed to be preserved, as for awake craniotomy , 
awake carotid endarterectomy  and for vitreoretinal surgey. In addition, 
dexmedetomidine was used for sedation in difficult airway patients; during 
fiberoptic intubation, and for sedation of a patient with difficult airway 
undergoing lumbar laminectomy surgery in the prone chest position under 
spinal anesthesia.  
4 .Use of dexmedetomidine as a sole anesthetic agent 
Dexmedetomidine used as a sole anesthetic agent. Does not produce any 
respiratory depression, hypotension and severe bradycardia. These effects were 
maintained at higher doses without hemodynamic instability.It can be safely 
used in patients who are susceotible  to narcotic induced respiratory depression.  
C. Use of dexmedetomidine in  postoperative period 
Dexmedetomidine in addition to its sympatholytic effects, analgesic 
effects and decreased rate of shivering, the preservation of respiratory function 
allows the continuation of the dexmedetomidine infusion in the extubated, 
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spontaneously breathing patient. The possibility of ongoing sedation and 
sympathetic block could be beneficial in reducing high rates of early 
postoperative ischemic events in high-risk patients undergoing non-cardiac 
surgery.  
Perioperative administration of dexmedetomidine could be beneficial in 
chronic opioid users and alcoholics, in high-risk patients as well as in cardiac 
patients with good to moderately decreased left ventricular function. 
D. Use of Dexmedetomidine in the pediatric-age group 
In pediatric-age group uses of intraoperative dexmedetomidine at 
different doses with the goal of reducing the post sevoflurane agitation in 
children aged 1-10 years. The optimal dose of dexmedetomidine was 0.3 μg/ kg 
and its use did not result in adverse effects. When compared with propofol for 
sedation during MRI, dexmedetomidine provides adequate sedation during the 
scan but has a slower recovery profile. 
One of the major advantages of dexmedetomidine over other sedatives is 
its respiratory effects, which are minimal in adults and children. It does not lead 
to extreme hypoxia or hypercapnia. Indeed, respiratory rate, CO2 tension, and 
oxygen saturation are generally maintained during dexmedetomidine sedation in 
children. 
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CONTRAINDICATIONS 
A. Severe bradycardia and cardiac conduction abnormalities. 
B. Ventricular dysfunctions - ejection fraction<30%. 
C. Patients with hypovolemia or hypotension. 
ADVERSE EFFECTS 
1. Central and Peripheral nervous system: Dizziness, headache, 
neuralgia, neuritis, speech disorder,   Convulsion 
2. Gastrointestinal System : 
Abdominal pain, diarrhea, vomiting, nausea, dry mouth 
3. Cardiovascular systems:  
Arrhythmia, ventricular arrhythmia, bradycardia, hypoxia, 
atrioventricular block,  cardiac arrest,  extrasystoles,   atrial 
fibrillation, heart block, Twave inversion, tachycardia, 
supraventricular tachycardia, ventricular tachycardia 
4. Hepato Biliary System: 
Increased gamma glutamyl transpepsidase,  hepatic function 
abnormal, hyperbilirubinemia, alanine transaminase, aspartate 
aminotransferase. 
5. Metabolic and Nutritional Disorder: 
Acidosis, respiratory acidosis, hyperkalemia, increased alkaline             
phosphatase, thirst, and hypoglycemia. 
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6. Psychiatric Disorders: 
Agitation, confusion, hallucination, illusion. 
7. Blood: Anemia. 
8. Renal system: Blood urea nitrogen elevated, oliguria. 
9. Respiratory System: Apnea, bronchospasm, dyspnea, hypercapnia. 
10. Vision Disorders: Photopsia, abnormal vision                 
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7. REVIEW OF LITERATURE 
1. Journal of clinical anaesthesiolgy and pharmacology.2010, 26(2).149-
53. Dhurjoti prosad et al. Studied 90 children for caudal analgesia in  age group 
between one to six years and divided into three groups. Group R received 
0.25%of ropivacaine  1ml/kg , Group C  received 0.25%of ropivacaine  1ml/kg 
with  clonidine  1 mcg/kg and  group D is received 0.25% of ropivacaine 1ml/kg 
with dexmedetomidine1mcg/kg. This study results concluded the duration of 
analgesia was 6 ± 0.46 hours in Group R , Group C is 13.17 ± 0.68 hours and 
Group D  15.26±0.86 hours.Addition of dexmedetomidine and clonidine with 
ropivacaine in caudal anaaethesia better than ropivacaine alone and   without 
any hemodynamic instability.   
2. Journal of acta anaeathesia scandinavica.2009.53 (2), 251-256. Boles, 
Saadway et al , studied the effect of dexmedetomidine  combined  with 
bupivacaine in caudal anaesthesia in children . In this study results were 
excellent intraoperative and postoperative analgesia and without any adverse 
effects. 
3. British journal anaesthesia 2009, 103(2) .268-274.  A M  Abd  
Elwahab et al, studied 60 patients randomized  selected age between 6 months 
to six years for infra umbilical  surgeries. It is divided into two groups. Group C  
received bupivacaine 0.25% 1ml/kg with clonidine 2 mcg/kg and Group D  
received bupivacaine 0.25% 1ml/kg added with dexmedetomidine 2 mcg/kg in 
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caudal anaesthesia. This study  showed that  dexmedetomidine group had 
prolonged duration of post operative analgesia than the clonidine group, without 
any significant side effects. 
4. Anaesthesia and analgesia 2007, 14.1356-1363.Thomas et al. a 
comparative study of single shot caudal epidural clonidine ,morphine and 
hydromorphine with ropivacaine in caudal anaesthesia in children age  between 
6 months to six years .It was a double blind randomized controlled study 
divided into three groups, clonidine 2mcg/kg, morphine 50mcg/kg, 
hydromorphine 10mcg/kg with 0.25%of ropivacaine in adrenaline. Results of in 
this study was clonidine combined with ropivacaine  to produce the increases 
duration of analgesia without significant side effects. Caudal opioid produced 
the postoperative nausea and vomiting. 
5.  Peadiatric anaesthesiology 2005, vlume 15(7), page 580-585. Nursel et 
al.  Comparison between clonidine and ketamine with ropivacaine in caudal 
anaesthesia for children .the randomized controlled study divided into three 
groups. Group R is received 0.75ml/kg of 0.25%   ropivacaine . Group RC is 
received 0.75ml/kg of 0.25%   ropivacaine with mcg/kg clonidine  and Group 
RK is received 0.75ml/kg  of 0.25%   ropivacaine with ketamine 0.5mg /kg. All 
three groups monitored the insulin, glucose, cortisol, sedation levels and 
complications. Results of this study are clonidine and ketamine group is 
prolonged duration of analgesia and attenuate the stress response to surgery. 
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6. European journal of anaesthesia. 2010. 27, (11), 560. Erbek et al 
studied comparison between bupivacaine 0.5% and dexmedetomidine sedation 
for septoplasty procedure. The patients divided randomized into two groups. 
Group B patients received 0.5% bupivacaine alone and grooup BD patients 
received       0.5% bupivacaine with dexmedetomidine 2mcg/kg. Results of this 
study were bupivacaine combined with dexmedetomidine is better 
intraoperative, postoperative pain relief and reduce the intraoperative bleeding 
than bupivacaine alone. 
7. Indian journal of anaesthesiology. 2010, 53(3) page 226-230. Jabir 
kaur et al. studied to determine the quantitative and qualitative of caudal 
epidural anaesthesia, hemodynamic effects and postoperative duration of 
analgesia. This is randomised controlled double blind study for children age 
between one to nine years divided into two group, group I received 0.25% of 
ropivacaine and group II received 0.25% of ropivacaine with clonidine 2mcg/kg 
.the results of this study is duration of analgesia in group II is prolonged the 
duration of postoperative analgesia and efficient intraoperative analgesia 
without significant hemodynamic changes. 
8. Indian journal of anaesthesiology. 2009. 53(4) :450-459. Deepanjali 
pant et al studied forty children randomized selected and evaluated for caudal 
clonidine analgesic effects, hemodynamic effects and respiratory status of the 
children in day care pediatric surgeries. Divided into the two groups. Group B 
children are received 0.25%of bupivacaine 0.75ml and Group C are received 
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0.25% of bupivacaine 0.75ml with clonidine 2mcg/kg. Postoperatively 
monitoring for OPS score, sedation score, pulse rate and blood pressure were 
recorded. This study concluded that the duration of analgesia in group C was 
10.25 hours compared with group B was 4.55 hours and without hemodynamic 
instability. 
9. British journal of anaesthesia.2011. 106.  N Kumar et al. This is 
randomized controlled prospective study was selected 50 patients for upper 
abdominal surgeries and divided into two groups. Group BM patients are 
received 0.25% of bupivacaine 1.25ml/kg with morphine 30mcg/kg   and Group 
BC 0.25% of bupivacaine 1.25ml/kg with clonidine2 mcg/kg. In this study was 
concluded group BC was prolonged duration of post operative analgesia than 
group BM. The morphine group was produced more nausea and vomiting. 
10. Journal of acta anaesthesia scandinavica 2006.50(4); 501-
501.Korkmaz F et al. This is randomized, prospective, controlled study for 
prolong duration of analgesia for caudal clonidine combined with isobaric 
bupivacaine.Totaly sixty children was selected and divided into the two groups. 
Group B are received 1ml/kg of 0.125% isobaric bupivacaine and  group BC are 
received1ml/kg   of 0.125%  isobaric bupivacaine  with 2mcg/kg of clonidine. 
Results in this study the duration of analgesia prolonged in bupivacaine with 
clonidine 650 minutes without significant hemodynamic instability for 
intraoperative and postoperative periods   
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11. Indian journal of anaesthesiology 2011, 55.226-230.   Vijay anand G 
et al.The prospective ,randomized controlled , double blind study wre to 
comparison of caudal 0.25% of isobaric ropivacaine with dexmedetomidine  
undergoing lower abdominal surgeries in sixty children  age between six 
months to six years ,divided into two groups.  Group R are   received 0.25% of 
ropivacaine 1ml/kg and group RD   are received 0.25% of ropivacaine 1ml/kg 
with dexmedetomidine 2mcg/kg. Concluded from in this study the duration of 
postoperative analgesia in group RD was 14.5hours compare than group R was 
5.5 hours without any hemodynamic instability.  
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8. MATERIALS AND METHODS 
This Prospective, randomised, double blind, comparitive study was done 
to compare the efficacy and safety of dexmeditomidine and clonidine as 
ajuvants to caudal ropivacaine in postoperative analgesia for children. The study 
was carried out in 60 children at Government Rajaji hospital, Madurai for 
surgeries of lower abdomen and perineum in the year 2012. The children in the 
age group of 1-6 years and weighing 5-20Kgs were selected for the study. 
INCLUSION CRITERIA: 
Elective infra umbilical surgeries 
Both sexes 
Age: Between one to six years. 
ASA: I 
Weight: 5-20kg 
Exclusion CRITERIA: 
1. Known allergic to LA. 
2. Local sepsis. 
3. Neurological diseases. 
4. Bleeding disorders. 
5. Skeletal deformities 
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Only ASA I physical status patients were chosen to avoid the influence of 
the associated diseases. The sixty children were divided into two groups of 
thirty each.  
Group RC:  Received 1ml/kg of 0.25% ropivacaine and 1μg/ kg 
clonidine. Group RD: Received 1ml/kg of 0.25% ropivacaine and 1 μg/ kg 
dexmedetomidine.  
 Pre anaesthetic evaluation 
1. History. 
2. Clinical examination. 
3. Relevant investigations – haemoglobin, urine analysis. 
4. Informed consent from parents. 
5. All children were kept nil per oral for 6 hrs prior to surgery. 
 Children premedicated with 0.5mg/kg of oral midazolam 45 minutes 
before anaesthetic procedures. On arrival in the operation theatre, routine 
monitors (ECG, pulse oxymetry, NIBP) were attached and baseline vital 
parameters like mean arterial blood pressure (MAP), heart rate(HR) and arterial 
oxygen saturation (SPO2) were recorded. Induction was done by increasing 
concentration of sevoflurane (3 -8 %) along with oxygen and nitrous oxide 
mixture (40:60) through ayres T piece with Jackson Rees modification and 
facemask. After induction, an intravenous line was secured. Injection 
atracurium 0.5 mg / kg was administered to facilitate endotracheal intubation 
with appropriate size endotracheal tube. 
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Anaesthesia was maintained with 60%, nitrous oxide in40% oxygen and 
0.6%.Sevoflurane using controlled ventilation. The patients were positioned in 
left lateral position. After aseptic draping, a 23G needle was introduced into 
caudal space and either or ropivacaine with clonidine (Group RC) or 
ropivacaine with dexmedetomidine (group RD) was administered. At the end of 
the operation, residual neuromuscular block was reversed by appropriate doses 
of neostigmine 40µg/kg & atropine 10µg/kg and tracheal extubation was 
performed. Postoperatively they were monitored in postanasthetic care unit. 
Pulse rate, MAP and SPO2 were recorded throughout the operation at an 
interval of five minutes 
Intraoperative monitoring: 
Pulse rate, blood pressure, saturation. Decrease of mean arterial blood 
pressure and pulse rate more than 30% from the baseline values were defined as 
severe hypotension and bradycardia, respectively which were treated injection 
atropine sulphate 20mcg/kg. At the beginning of skin closure anaesthesia was 
discontinued. 
Postoperative monitoring was done in post anaesthetic care unit where 
vital parameters and pain, sedation scoring  done  every 15 minutes  for 3 hours 
and then every one  hour. 
1. Time from caudal block to end of the surgery. 
2. Sedation was assessed by 4 point scale. 
3. Pain was assessed by cries scale. 
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4. Duration of post-op analgesia. 
5. Pulse rate, map and spo2. 
6. Complications.  
The following parameters were assessed 
 4 point sedation scale: 
1. Barely arousable. (Sleeps Needs  shaking or shouting to arouse). 
2. Asleep. (Eyes closed arousable with soft voice or light touch). 
3. Sleepy. (Eyes open but less active and responsive). 
4. Awake. 
CRIES pain scale: 
 
 0 1 2 
Crying No High pitched Inconsolable 
Requires O2 for 
SPO2 >95% 
No < 30% of O2 > 30% of O2 
Increased vital 
signs 
No increase in HR 
and MAP 
↑ HR or MAP < 
20% 
↑ HR or MAP > 
20% 
Expression None Grimace Grimace/grunt 
Sleepless No Wakes up at frequent intervals Constantly awake 
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Score 0- signifies excellent analgesia. 
Score 10- indicate ineffective analgesia. 
Rescue analgesia with syrup paracetamol (15mg/kg) was given when the 
pain score was 4 or more. 
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9. STASTISTICAL ANALAYSIS 
Statistical Tools (To be included at the end of Materials and Methods)
 The information collected regarding all the selected cases were recorded 
in a Master Chart. Data analysis was done with the help of computer using 
Epidemiological Information Package (EPI 2010) developed by Centre for 
Disease Control, Atlanta.  
Using this software range, frequencies, percentages, means, standard 
deviations, chi square and p’ values were calculated. Kruskul Wallis chi-square 
test was used to test the significance of difference between quantitative 
variables and Yate’s chi square test for qualitative variables. A 'p' value less 
than 0.05 is taken to denote significant relationship. 
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10. OBSERVATION AND RESULTS 
The two groups were compared in characteristics like demographic data 
and basic vital parameters (pulse rate, MAP, saturation) and duration of surgery, 
duration of postoperative analgesia, complications. 
Table-1 DEMOGRAPHIC VARIABLES 
Variable Group RD Group RC P Significance 
Age (years) 3.47 3.73 0.5283 Not significant 
Sex 
Male 
Female 
 
25 
5 
 
24 
6 
 
0.7408 
Not significant 
Weight (kg) 14.77± 3.57 15± 3.73 0.7608 Not significant 
 
The mean age of children in group RD was 3.47 years and in group RC 
was 3.73 years which is found not to be statically significant with P value of 
0.5283. 
The sex distribution in group RD 25 males and 5females and in group RC 
were compared and found 24 males and 6 females. Both group were compared 
and found not to be statistically significant. 
The mean weights of children were 14.77 ±3.57 kg in group RD and 15± 
3.73 kg in group RC. Both group were compared and found not to be 
statistically significant. 
GRAPH 1:  AGE DISTRIBUTION 
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TABLE 2: PROCEDURE DONE 
Procedure 
Group RC Group RD 
No % No % 
Circumcission 16 53.3 15 50 
Left Herniotomy 5 16.7 7 23.3 
Right Herniotomy 9 30 8 26.7 
Total 30 100 30 100 
 
The procedures done in group RC herniotomy for 14 children and 
circumcission for 16 children . In group RD herniotomy for 15 children and  
circumcision for 15 children 
  
GRAPH 4: PROCEDURE DONE 
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B: HAEMODYNAMIC CHANGES 
Table 3: Preoperative, Intra operative and postoperative 
changes in pulse rate 
Pulse rate 
Pulse rate of 
‘p’ Group RC Group RD 
Mean SD Mean SD 
Pre op 0 hour 106.0 4.8 106.9 5.2 
0.4399 
Not significant 
Intra op 5min 104.5 4.8 104.2 4.2 
0.9289 
Not significant 
 
10 min 95.8 1.6 95.9  
0.6476 
Not significant 
15 min 93.8 2.1 94.0  
0.6644 
Not significant 
20 min 92.5 1.4 92.8  
0.988 
Not significant 
25 min 92.5 1.9 92.1  
0.2787 
Not significant 
30 min 92.3 1.6 91.8  
0.2975 
Not significant 
45 min 91.3 1.4 91.1 1.3 
0.5577 
Not significant 
Post op 
60 minutes 
91.2 1.7 90.9 1.4 
0.6357 
Not significant 
75min 91.2 1.8 90.8 1.5 
0.2985 
Not significant 
90 min 90.8 1.5 90.7 1.3 
0.7373 
Not significant 
105 min 90.7 1.7 90.5 1.4 
0.659 
Not significant 
120min 91.4 1.6 90.6 1.3 
0.0476 
Not significant 
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135min 90.5 1.4 90.4 1.3 
0.7342 
Not significant 
150 min 90.4 1.4 90.4 1.4 
1.0 
Not significant 
165 min 90.7 1.5 90.4 1.0 
0.7111 
Not significant 
180 min 91.1 1.9 90.3 1.4 
0.1023 
Not significant 
4 hours 90.7 1.7 90.5 1.4 
0.659 
Not significant 
5 hours 91.4 1.6 90.6 1.3 
0.0476 
Not significant 
6 hours 90.5 1.4 90.4 1.3 
0.7342 
Not significant 
7 hours 90.4 1.4 90.4 1.4 
1.0 
Not significant 
8 hours 90.7 1.5 90.4 1.0 
0.7111 
Not significant 
9 hours 91.1 1.9 90.3 1.4 
0.1023 
Not significant 
10 hours 93.4 1.8 90.6 1.5 0.0001Significant
11 hours 100.1 2.9 90.6 1.3 0.0001Significant
12 hours 103.0 3.3 90.3 1.2 0.0001Significant
13 hours 101.1 3.6 90.2 1.1 0.0001Significant
14 hours 102.8 3.4 90.4 0.9 0.0001Significant
15 hours 103.4 3.9 96.2 1.6 0.0001Significant
16 hours 104.1 4.4 99.7 2.2 0.0001Significant
17 hours 104.2 4.7 99.8 2.2 0.0001Significant
 
  
GRAPH 5:  CHANGES IN PULSE RATE PRE, 
INTRA, POST OPERATIVE PERIOD 
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Table 4: Pre operative and intra operative, post operative  
changes in mean arterial pressure 
 
MAP 
MAP of  
‘p’ Group RC Group RD 
Mean SD Mean SD 
Pre op. 
0min 
 
85.7 
 
3.7 
 
84.7 
 
3.1 
0.3529 
Not significant 
Intra op 
5min 
81.3 2.3 80.5 1.7 0.1764 
Not significant 
 
10 min 
75.4 1.8 74.7 2.1 0.2209 
Not significant 
 
15 min 
74.4 1.9 74.8 1.8 0.3302 
Not significant 
 
20 min 
73.8 1.4 74.0 1.5 0.8255 
Not significant 
 
25 min 
74.2 1.1 74.4 1.2 0.7653 
Not significant 
 
30 min 
73.0 1.2 73.3 1.1 0.3183 
Not significant 
 
45 min 
73.0 0.9 73.0 0.9 0.8695  
Not significant 
Post op 
60 minutes 
73.1 1.0 72.9 0.9 0.5754 
Not significant 
75 minutes 73.0 1.0 72.9 0.9 0.6754 Not significant 
90mins 
72.9 0.8 72.8 0.8 0.5855 
Not significant 
105 min 72.9 1.0 72.7 0.9 0.3395 Not significant 
120min 
73.1 1.1 73.2 0.8 0.9319 
Not significant 
135 min 
72.8 1.0 72.7 0.9 0.6701 
Not significant 
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150min 72.7 0.8 72.8 0.7 0.6318 Not significant 
165 min 
73.0 0.9 73 0.7 0.9556 
Not significant 
180 min 72.8 0.9 72.9 0.9 0.9317 Not significant 
4 hours 73.1 1.1 73.2 0.8 0.9319 Not significant 
5 hours 72.8 1.0 72.7 0.9 0.6701 Not significant 
6 hours 72.7 0.8 72.8 0.7 0.6318 Not significant 
7 hours 73.0 0.9 73 0.7 0.9556 Not significant 
8 hours 72.8 0.9 72.9 0.9 0.9317 Not significant 
9 hours 
72.7 0.9 72.6 0.7 0.6499 
Not significant 
10 hours 72.8 1.0 72.7 0.9 0.6701 Not significant 
11 hours 
72.7 0.8 72.8 0.7 0.6318 
Not significant 
12 hours 73.0 0.9 73 0.7 0.9556 Not significant 
13 hours 81.6 3.2 72.5 0.9 0.0011Significant 
14 hours 82.3 2.7 74.9 1.2 0.0001Significant 
15 hours 82.1 2.9 78.3 0.8 0.0001Significant 
16 hours 84.0 2.8 81.8 2.4 0.0011Significant 
17 hours 85.6 3.3 82.8 2.5 0.0001Significant 
 
 
 
GRAPH 6: MEAN ARTERIAL PRESSURE 
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Table 3 & 4 
 The hemodynamic changes of Pulse rate and mean arterial pressure 
between both groups were compared in   preoperative, intra operative and 
postoperative periods and significant changes were found only at 9th to 17th 
hours. 
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Table 5: Pre operative and Intra operative changes in SPO2 
 
SPO2 
SPO2 
‘p’ Group RC Group RD
Mean SD Mean SD
Pre op. 0 hour 97.8 1.1 97.6 1.1 1.0Notsignificant
Intra Op 
5 min 
98.6 0.5 98.4 0.4 1.0 
Not significant 
10 minutes 98.6 0.5 98.3 0.4 1.0 
Not significant 
15 minutes 98.7 0.5 98.7 0.5 1.0 
Not significant 
20 minutes 98.6 0.5 98.5 0.4 1.0 
Not significant 
25 minutes 98.8 0.4 98.7 0.4 1.0 
Not significant 
30 minutes 98.8 0.5 98.5 0.4 1.0 
Not significant 
45 minutes 98.6 0.4 98.7 0.5 1.0 
Not significant 
60 minutes 98.7 0.4 98.4 0.4 1.0 
Not significant 
75min 98.7 0.4 98.4 0.4 1.0 
Not significant 
90min 98.8 0.4 98.6 0.4 1.0 
Not significant 
105 min 98.8 0.4 98.5 0.4 1.0 
Not significant 
120MIN 98.9 0.3 98.6 0.3 1.0 
Not significant 
135min 98.9 0.3 98.6 0.3 1.0 
Not 
significant 
150 min 98.9 0.3 98.8 0.3 1.0 
Not significant 
165min 98.9 0.3 98.5 0.3 1.0 
Not significant 
180min 98.9 0.3 98.4 0.3 1.0 
Not significant 
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Table 5 (a) Post operative changes in SPO2 
 
Post op. SPO2 at 
Post operative SPO2 of  
‘p’ Group RC Group RDMean SD Mean SD
4 hours 98.9 0.3 98.8 0.2 1.0 Not significant 
5 hours 98.9 0.3 98.7 0.2 1.0 Not significant 
6 hours 98.9 0.3 98.8 0.2 1.0 Not significant 
7 hours 98.9 0.3 98.7 0.3 1.0 Not significant 
8 hours 98.9 0.3 98.6 0.3 1.0 Not significant 
9 hours 98.9 0.3 98.8 0.3 1.0 Not significant 
10 hours 99.6 0.2 99.4 0.2 1.0 Not significant 
11 hours 99.4 0.2 99.3 0.2 1.0 Not significant 
13 hours 98.9 0.3 98.7 0.3 1.0 Not significant 
14 hours 99.0 0.2 98.9 0.3 1.0 Not significant 
15 hours 99.2 0.2 99.2 0.2 1.0 Not significant 
16 hours 99.4 0.3 98.9 0.3 1.0 Not significant 
17 hours 99.0 0/2 98.9 0.3 1.0 Not significant 
 
The saturation was compared between both groups pre operative, intra 
operative and post operative period were compared and found not to be 
statistically significant. 
 
  
GRAPH 7: SPO2 
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C: COMPARATIVE EFFICACY 
Table 6:  Duration of surgery 
 
Parameter 
Duration of surgery ( in 
minutes) 
Group RC Group RD 
Range 20-45 20-45 
Mean 31.0 30.0 
SD 8.14 7.88 
‘p’ 0.6244  Not significant 
Table 6 
 The mean duration of surgery in group RD was 31 minutes and RC 30 
minutes, which was found not to be statistically significant. 
  
GRAPH 8: DURATION OF SURGERY 
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Table 7: Duration of postoperative analgesia  
Parameter Duration of Post Operative 
analysis ( in hours) 
Group RC Group RD 
Range 8-12 13-17 
Mean 9.8 14.67 
SD 1.4 1.15 
‘p’ 0.0001  Significant 
Table 7 
The mean duration of post-operative analgesia was 14.67±1.4 hours in 
group RD and 9.8±1.15 hours in group RC. Both group were compared and 
found that dexmedetomidine group had a longer duration of postoperative 
analgesia,which is  statistically significant. 
 
  
GRAPH 9: DURATION OF POSTOPERATIVE ANALGESIA 
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TABLE 8 : 4 POINT SEDATION SCORE  
 
TIME IN 
HOURS 
 
GROUP   RD 
 
GROUP   RC 
1 2 3 4 1 2 3 4 
1hr 30 0 0 0 30 0 0 0 
3hr 30 0 0 0 25 5 0 0 
6hr 24 6 0 0 18 10 2 0 
12hr 0 20 10 0 0 15 12 3 
17hr 0 0 10 20 0 0 8 22 
 P VALUE 1.0       NOT SIGNIFICANT 
 
The Sedation score was compared between GROUP RD & GROUP RC 
in postoperative periods and found not to be statistically significant. 
  
GRAPH:10 GROUP RD SEDATION SCORE 
 
 
 
 
 
 
 
 
 
 
 
 
 
GRAPH 10a: GROUP RC SEDATION SCORE 
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Table 9:  CRIES Pain scale 
Pain scale Group RC Group RD No % No % 
0 14 46.7 20 66.7 
1 15 50 10 33.3 
2 1 3.3 - - 
Total 30 100 30 100 
Range 0-2 0-1 
Mean 0.57 0.33 
SD 0.57 0.48 
‘p’ 0.1039 Not significant 
 
The CRIES pain scale was compared between two groups and found not 
to be statistically significant. 
 
  
GRAPH 11: CRIES PAIN SCALE 
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Table 10 : Complications 
Complications Group RC Group RD 
No % No % 
Nausea 1 3.3 2 6.7 
Nausea & Vomiting 1 3.3 - - 
Pruritis 1 3.3 1 3.3 
Nil 27 90 27 90 
Total 30 100 30 100 
‘p’ 1.0 Not significant 
 
The complications in two groups were compared and found not to be 
statistically significant. 
  
GRAPH 12: COMPLICATIONS 
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11. DISCUSSION 
Postoperative analgesia provides not only pain relief but also inhibits 
trauma induced  nociceptive impulses to blunt autonomic reflexes. It allows the 
patients to breath and move freely to enhance early restoration of function. 
Untreated postoperative pains produce the several detrimental acute and 
chronic effects. Neuroendocrine responses to pain result in increases 
sympathetic tone, increased catecholamine and catabolic hormone secretions 
and decreased secretion of  the anabolic hormones.  
The neuroendocrine stress response may potentiate to other detrimental 
physiological effects like hypercoagulability, immunosuppressant, and delay in 
return of gastrointestinal function. Decreased postoperative respiratory function 
is markedly especially after abdominal and upper thoracic surgeries. Children 
with poor postoperative pain control may breathe less deeply have an 
inadequate cough and be more susceptible to the development of post operative 
pulmonary complications. Inadequate postoperative pain relief produce the long 
term consequences like that eating disturbance, altered the sleeping pattern and 
increased pain perception during subsequent painful experiences. 
The benefits of paediatric regional analgesia for children include safety, 
and efficacy with no increased risk when compared with general anaesthesia 
alone but requires technical expertise. Children should faster recovery, shorter 
hospital ICU stay , and reduced ventilator requirement when supplemented with 
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regional anaesthesia .the spectrum of autonomic ,hormonal, metabolic, 
immunologic/inflammatory, and neurobehavioral consequences caused due to 
surgical stress can be decreased by regional anaesthesia. 
Benefits of regional anaesthesia is not only pain relief it  also reduction of 
general   anaesthetic requirement ,may reduce the toxicity of general anaesthetic 
agents, reduce the  neurohormonal   stress responses ,improve the                     
gastrointestinal functions, reduction of intraoperative blood loss and improve 
the defence mechanisms.          
Enteral and parenteral analgesics used in postoperative analgesia, are 
associated side effects like gastrointestinal bleeding, nausea and vomiting, 
sedation, precipitation of asthma tic attack,  respiratory depression, 
thrombocytopenia and nephrotoxicity , hepatotoxicity, etc.  
Several local anaesthetic agents like lidocaine, bupivacaine and 
ropivacaine  have been used for caudal block. Adjuvants like opioids , 
clonidine,  dexmedetomidine, midazolam  and ketamine  are added to local 
anaesthetic agents to the duration of analgesia was increased, decrease the 
individual dose of the drug and thereby decreasing the side effects. 
Dexmedetomidine and Clonidine is an effective adjuvant to local  
anaesthetic agents when administered for caudal block. Addition of both has 
been found to increase the duration of analgesia without any increase in the side 
effects. When administered caudally, both produces analgesia by interacting 
with alpha 2 adrenergic receptors. These receptors are located on the superficial 
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laminae of spinal cord and brain stem nuclei implicated in pain, so analgesia can 
be produced at peripheral, spinal and brain stem sites. 
Ideal anaesthetic technique should be targeted at three sites periphery,  
sensory flow in nerves and cells in the central nervous system. The 
administration of an  analgesic before any tissue damage  takes  place  could  
interfere with and reduce the magnitude of nociception  and thereby prevent a 
state of  hypersensitisation. 
 The various methods of providing pain relief have some side effects 
whichprohibit their use, for eg, narcotics in children, because of their respiratory 
depression, the  objection  to  needles  in  the case  of   parenterally administered  
analgesics.  
Caudal anaesthesia was chosen for this study as it is the simplest and 
safest techniques in paediatric surgery with a success rate of single shot caudal 
epidural injection of local anaesthetic agents and additives that prolong the 
postoperative analgesia. By this regional technique, problems and complications 
of intubation and polypharmacy due to general anaesthesia are avoided. 
   In this study, we used clonidine and dexmedetomidine was used in the 
dose of 1μg /kg along with 0.25% ropivacaine and did not observe significant 
incidence of adverse effects like hypotension, bradycardia and respiratory 
depression, 
Lee et al. This study  administered clonidine dose of 2μg /kg along with 
bupivacaine in children undergoing lower limb orthopaedic surgery in their 
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study. They observed higher incidence of bradycardia and hypotension 
associated with 2μg /kg dose of clonidine added to bupivacaine. 
     The two groups were compared with respect to weight, sex, age, and, 
duration of post operative analgesia, duration of surgery, complications.  The 
pre operative, intra and postoperative pulse rate, mean arterial pressure and 
saturation and complication were also compared. 
SEDATION: 
Sedation and hence patient comfortability as assessd from 4 point 
sedation score. It was not significant in both groups.  
ANALGESIA:  
Pain intensity was assessed in this study by CRIES scale. This scale is a 
reliable and a sensitive tool for evaluvation of postoperative pain in children. 
The mean duration and SD of analgesia for caudal RC was 9.8 ± 
1.4hours. In group RD mean duration and SD of analgesia was 14.67± 1.15 
hours. 
The results of the study done by Mausumi Neogi et al. Journal of  
Anaesthesia and  Clinical  Pharmacology 2010; 26(2): 149-153   results of the 
mean duration of analgesia was  6.32±0.46 hours in group Ropivacaine, 
13.17±0.68 hours in group Clonidine and 15.26±0.86 hours in group 
Dexmedetomidine. The prolongation of duration of analgesia was significant in 
both group clonidine and dexmedetomidine was compared to group ropivacaine. 
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Vijay anand et al .Indian journal of anaesthesia 2011,55:226-230. Results 
of this study duration of postoperative analgesia in ropivacaine combined with 
demedetomidine is14.5±0.5hours than ropivacaine group is 5.5±0.5 hours and  
less emergence agitation following sevoflurane inhalation anaesthesia. 
HAEMODYNAMIC STABILITY: 
In both the groups there was not significant alteration in the intra operative 
and Postoperative pulse rate, mean arterial pressures and saturation. The 
difference found at 9th to 17th hours of post operative period  pulse rate, mean 
arterial pressures was significant because of group RD was increase duration of 
analgesia and comportability better than clonidine group. But both group does 
not cause any hypotension bradycardia and respiratory depression. 
COMPLICATION: 
There were no significant complications in both groups were noted. 
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12. SUMMARY 
 This study was carried out at Government Rajaji hospital, Madurai, in 60 
children between one to six years of age with ASA physical status I grading, the 
procedure  underwent by children were infraumblical surgeries. They were 
divided into the two groups of thirty each group. Group RC (1ml/ kg of 0.25% 
ropivacaine and 1μg/ kg clonidine), Group RD (1ml/kg of 0.25% ropivacaine 
and 1 μg/ kg dexmedetomidine) as above. All children were given general 
anaesthesia and maintained with sevoflurane 0.6% and 60% N₂O in 40% O₂ and 
atracurium. This study showed that 
1. Dexmedetomidine when added with caudal ropivacaine provided longer  
duration of analgesia than Clonidine with ropivacaine . 
2. Patient comfortability in terms of sedation and duration of analgesia was 
better in dexmedetomidine group than clonidine group. 
3. Cardiovascular stability was similar in both the groups. 
4. There were no significant complications in both groups. 
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13.  CONCLUSION 
 
From this study it is concluded that dexmeditomedine added to 
ropivacaine in caudal anaesthesia appears to provide efficious pain relief and 
comfortability for longer duration than clonidine added to ropivacaine in 
children undergoing infraumblical surgeries without any significant side effects. 
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STUDY PROFOMA 
Comparative study of Clonidine and Dexmedetomidine as Adjuncts to 
Ropivacaine in Caudal Analgesia in children. 
NAME: AGE:  SEX: WT: 
DIAGNOSIS:  SURGERY:  
INFORMER:    
Pre op:     
PR - BP - SPO2 –  
General Anaesthesia: 
 
Induction – sevoflurane 3- 8%  with oxygen and nitrous oxide mixture 
(40:60). After induction, Inj atracurium 0.5 mg/ kg was given for intubation. 
Maintainance with 60% N2O, 40% O2.and sevoflurane 0.6% 
 
Caudal block: 
 
Group RC:  1ml / kg of 0.25% ropivacaine and 1 mcg/kg clonidine . 
Group RD:  1ml/kg of 0.25% ropivacaine and 1 mcg/kg 
dexmedetomidine . 
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Monitoring: 
 
 5 min 10 15 20 25 30 35 40 45 
HR          
MAP          
Spo2          
 
Time of caudal block -  
Time from caudal block to end of surgery –  
Sedation was assessed by 4 point sedation scale. 
 
1. Barely arousable. (Sleep, Needs shaking or shouting to arouse) 
2. Asleep. (Eyes closed, Arousable with soft voice or light touch) 
3. Sleepy. (Eyes open but less active and responsive) 
4. Awake. 
Pain assessed by CRIES pain scale 
 0 1 2 
Crying No  High pitched Inconsolable 
Requires O2 for  
SPO2 >95% 
No   Less than 30% of 
O2 
More than30% of 
O2 
Increased vital 
signs 
No ↑ HR and 
MAP 
↑ HR or MAP < 
20% 
↑HR or MAP > 
20% 
Expression None  Grimace Grimace and 
grunt 
Sleepless No  Wakes frequent 
intervals 
Awake 
 
Duration of Postoperative analgesia: 
Complication: 
1hr 3hr 6hr 12hr 17hr
1 MASILAMANI 2/Mch 11 11124 PHIMOSIS CIRCUMCISSION 25 15 1 1 1 2 3 0 NIL
2 SINDU 4/Fch 16 11326 LT. INGUINAL HERNIA LT. HERNIOTOMY 35 13 1 1 1 3 4 0 NIL
3 KANDASAMY 3/Mch 14 10136 LT. INGUINAL HERNIA LT. HERNIOTOMY 35 14 1 1 1 2 4 0 NIL
4 VIGNESH 1/Mch 10 10568 PHIMOSIS CIRCUMCISSION 20 14 1 1 1 2 3 1 NIL
5 SATISH 5/Mch 19 12476 RT. INGUINAL HERNIA RT. HERNIOTOMY 40 15 1 1 1 2 3 0 NIL
6 MARIMUTHU 6/Mch 20 12543 RT. INGUINAL HERNIA RT. HERNIOTOMY 45 13 1 1 1 3 4 0 PRURITUS
7 SARANRAJ 3/Mch 14 13456 PHIMOSIS CIRCUMCISSION 20 14 1 1 2 2 3 1 NIL
8 NAGARAJ 5/Mch 18 16789 PHIMOSIS CIRCUMCISSION 25 15 1 1 1 3 4 0 NIL
9 UDAYAKUMAR 2/Mch 12 17654 PHIMOSIS CIRCUMCISSION 25 16 1 1 1 2 4 1 NIL
10 SHANMUGAVEL 6/Mch 19 17658 LT. INGUINAL HERNIA LT. HERNIOTOMY 45 16 1 1 2 2 4 0 NIL
11 SANKARI 3/Fch 14 18673 RT. INGUINAL HERNIA RT. HERNIOTOMY 40 13 1 1 1 3 4 0 NIL
12 KRISHNASAMY 5/Mch 19 18345 PHIMOSIS CIRCUMCISSION 35 14 1 1 1 2 4 1 NIL
13 KARTHIKA 4/Fch 16 18961 LT. INGUINAL HERNIA LT. HERNIOTOMY 30 15 1 1 2 2 3 0 NIL
14 BALAJI 6/Mch 19 19043 PHIMOSIS CIRCUMCISSION 25 13 1 1 1 3 4 0 NIL
15 PRABU 1/Mch 9 18921 PHIMOSIS CIRCUMCISSION 20 13 1 1 1 2 4 0 NIL
16 KARTHIKEYAN 4/Mch 15 19563 RT. INGUINAL HERNIA RT. HERNIOTOMY 35 16 1 1 1 2 3 1 NIL
17 ARUN 2/Mch 11 20948 RT. INGUINAL HERNIA RT. HERNIOTOMY 45 15 1 1 1 2 3 0 NIL
18 SARANYA 4/Fch 17 22163 LT. INGUINAL HERNIA LT. HERNIOTOMY 25 16 1 1 1 3 4 1 NIL
19 KALAIVANI 1/Fch 8 23212 RT. INGUINAL HERNIA RT. HERNIOTOMY 30 14 1 1 2 2 4 0 NIL
20 TAMILARASAN 6/Mch 20 22478 RT. INGUINAL HERNIA RT. HERNIOTOMY 35 15 1 1 2 2 4 1 NAUSEA
21 ANTHONY 3/Mch 14 25983 PHIMOSIS CIRCUMCISSION 20 15 1 1 2 3 4 0 NAUSEA
22 NARESH 4/Mch 17 22314 RT. INGUINAL HERNIA RT. HERNIOTOMY 30 15 1 1 1 3 4 1 NIL
23 SUNDARARAJAN2/Mch 11 27612 PHIMOSIS CIRCUMCISSION 25 17 1 1 1 2 4 1 NIL
24 RAHIM 5/Mch 19 23317 PHIMOSIS CIRCUMCISSION 30 14 1 1 1 2 3 0 NIL
25 KRISHNAN 3/Mch 15 22456 PHIMOSIS CIRCUMCISSION 20 14 1 1 1 2 3 0 NIL
26 RAMANATHAN 4/Mch 16 24590 LT. INGUINAL HERNIA LT. HERNIOTOMY 35 16 1 1 1 3 4 0 NIL
27 GIRISH 1/Mch 9 23762 PHIMOSIS CIRCUMCISSION 25 14 1 1 1 3 4 0 NIL
28 KAMESH 4/Mch 16 24982 PHIMOSIS CIRCUMCISSION 20 15 1 1 1 2 4 0 NIL
29 VENKATESAN 3/Mch 13 25974 PHIMOSIS CIRCUMCISSION 30 17 1 1 2 2 4 1 NIL
30 DINESH 2/Mch 12 26518 LT. INGUINAL HERNIA LT. HERNIOTOMY 30 14 1 1 1 2 3 0 NIL
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1hr 3hr 6hr 12hr 17hr
1 ESAKI RAJA 3/Mch 14 10484 PHIMOSIS CIRCUMCISSION 25 10 1 1 1 2 3 0 NIL
2 JEGAN 5/Mch 18 12022 PHIMOSIS CIRCUMCISSION 30 11 1 1 1 2 4 0 NIL
3 MANOJ 2/Mch 11 13130 RT.INGUINAL HERNIA RT. HERNIOTOMY 45 12 1 1 1 2 3 0 NIL
4 ARAVIND 4/Mch 17 12569 PHIMOSIS CIRCUMCISSION 25 8 1 1 2 3 4 1 NIL
5 MURUGAN 5/Mch 16 12386 PHIMOSIS CIRCUMCISSION 25 10 1 1 1 2 4 1 NIL
6 BALA 3/Mch 15 12509 RT. INGUINAL HERNIA RT. HERNIOTOMY 40 9 1 1 3 4 4 0 NIL
7 LAKSHMAN 6/Mch 19 13423 RT. INGUINAL HERNIA RT. HERNIOTOMY 35 8 1 1 1 3 4 1 NAUSEA
8 KARUPPU 4/Mch 8 16089 PHIMOSIS CIRCUMCISSION 35 11 1 1 2 3 4 1 NIL
9 KARTHIK 5/Mch 19 16651 PHIMOSIS CIRCUMCISSION 25 10 1 1 1 2 4 1 NIL
10 VISHNU 4/Mch 16 15078 LT.INGUINAL HERNIA LT. HERNIOTOMY 40 8 1 1 2 3 4 1 NIL
11 MURTHY 2/Mch 10 16073 RT. INGUINAL HERNIA RT. HERNIOTOMY 35 11 1 1 1 2 3 1 NIL
12 BABU 6/Mch 20 16830 PHIMOSIS CIRCUMCISSION 20 9 1 1 1 2 3 0 NIL
13 KAVERI 6/Fch 18 17961 LT. INGUINAL HERNIA LT. HERNIOTOMY 35 8 1 1 3 4 4 0 NIL
14 PANDI 2/Fch 10 19053 RT.INGUINAL HERNIA RT. HERNIOTOMY 40 12 1 1 1 2 4 0 NIL
15 SANTHOSH 4/Mch 16 11621 PHIMOSIS CIRCUMCISSION 25 10 1 1 2 3 4 0 NIL
16 ILAYARASA 1/Mch 9 20569 PHIMOSIS CIRCUMCISSION 20 12 1 1 2 3 4 0 NIL
17 RAJA 5/Mch 18 20443 RT. INGUINAL HERNIA RT. HERNIOTOMY 30 11 1 1 1 2 4 1 NIL
18 VENKATESH 3/Mch 13 22062 PHIMOSIS CIRCUMCISSION 20 8 1 1 1 2 3 0 PRURITUS
19 NAZAR 6/Mch 20 21214 RT. INGUINAL HERNIA RT. HERNIOTOMY 35 9 1 1 2 3 4 1 NIL
20 ANBARASAN 4/Mch 17 22700 LT. INGUINAL HERNIA LT. HERNIOTOMY 45 9 1 1 2 3 4 1 NIL
21 RAJESH 2/Mch 11 23903 PHIMOSIS CIRCUMCISSION 30 10 1 1 1 2 3 1 NIL
22 SRIKANTH 4/Mch 15 22317 PHIMOSIS CIRCUMCISSION 25 10 1 1 3 4 4 0 NIL
23 SUNDARI 4/Fch 17 20512 RT. INGUINAL HERNIA RT. HERNIOTOMY 35 12 1 1 2 3 4 1 NIL
24 SARASWATHY 2/Fch 12 23346 LT. INGUINAL HERNIA LT. HERNIOTOMY 40 11 1 1 1 2 3 1 NIL
25 SHIVA 5/Mch 19 23445 PHIMOSIS CIRCUMCISSION 25 10 1 1 1 2 3 2 NAUSEA,
VOMITING
26 PALPANDI 6/Mch 19 23570 PHIMOSIS CIRCUMCISSION 20 8 1 1 2 3 4 0 NIL
27 PADMA 1/Fch 8 20452 RT. INGUINAL HERNIA RT. HERNIOTOMY 45 8 1 1 2 3 4 0 NIL
28 KUMAR 3/Mch 15 20765 PHIMOSIS CIRCUMCISSION 25 10 1 1 1 2 4 1 NIL
29 LAKSHMAN 2/Mch 12 23476 PHIMOSIS CIRCUMCISSION 20 11 1 1 2 3 4 1 NIL
30 KIRTHIKA 6/Fch 18 26403 LT. INGUINAL HERNIA LT. HERNIOTOMY 35 8 1 1 1 2 4 0 NIL
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